As the global plasmid market continues to grow rapidly, current and projected demand for high quality plasmid continues to be challenged by the availability of global supply. The Carlsbad, California site expands Thermo Fisher’s clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer treatments as well as mRNA vaccines. In addition, the site has the capability to produce large-scale plasmid DNA as a primary drug substance for DNA therapies.
The 67,000-square-foot facility in Carlsbad, CA will not only help alleviate capacity constraints but also address additional customer needs including:
Learn more about the capabilities at this site by downloading our complete Site Fact Sheet.